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Introduction The presence of Candida species in urine (candiduria) is a common clinical finding, which 
may frequently represent colonization or contamination of specimens, however, they may be etiologi-
cal agents in urinary tract infections (UTIs) or be indicators of underlying pathology in the genitourinary 
system or disseminated candidaemia. C. albicans is the most frequently isolated species of the genus, 
however, an increase in the occurrence of non-albicans Candida species (NACS) has been reported, 
which may be attributable to frequent exposure to fluconazole.
Material and methods The aim of this study was to retrospectively assess and compare the prevalence 
of candiduria and UTIs caused by Candida spp. among inpatients and outpatients at a major clinical 
center in Hungary, during a 10-year period (2008–2017).
Results Candiduria was detected in 0.11–0.75% of positive samples from outpatients, while this number 
was significantly higher for inpatients, ranging between 3.49–10.63% (p <0.001). Overall, C. albicans was 
the most frequently isolated species (65.22% in outpatients and 59.64% in inpatients), however, the 
presence of C. glabrata as a relevant etiologic agent (~20–30%) is also noteworthy, because there are cor-
responding therapeutic consequences.
Conclusions A pronounced female dominance (1.7–2.15-fold), advanced age (~70 years) and hospitaliza-
tion of affected patients during candiduria is in line with the findings in literature.
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ence of Candida species in urine (i.e., candiduria), 
is a common clinical finding, particularly in hospi-
talized patients, with some reports indicating that 
as many as 90% of patients with Candida urinary 
tract infections (UTIs) were hospitalized and had 
a urinary catheter [1, 4, 5, 6]. In adult patients, 
candiduria may frequently represent colonization 
or contamination of the specimen, especially if the 
patient has no symptoms [7]. Nevertheless, clinicians 
should not dismiss this clinical finding haphazardly, 
because the presence of yeasts in the urine may very 
well be due to their etiological significance in UTIs 
or be indicative of or an underlying pathology in the 
INTRODUCTION
The genus Candida – under physiological conditions 
– exist as saprophytes, colonizing mucosal surfaces 
and the external genitalia of humans of either gen-
der, but they are present abundantly near the ure-
thral meatus of healthy women of childbearing age 
[1, 2, 3]. In voided specimens of urine from healthy 
individuals, Candida species can be found in detect-
able quantities in <1% of cases. However, in a pri-
mary care setting, they account for 5% of all positive 
urine culture results and 10% or more in tertiary-
care hospitals and specialized centers [2]. The pres-
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spectively), primary and tertiary care university-
affiliated (University of Szeged) teaching hospi-
tal, servicing an urban and rural population in 
the southeast region of Hungary of about 400,000 
people [12]. Candiduria and Candida UTIs were 
identified retrospectively by reviewing the com-
puterized microbiology records of the Institute of 
Clinical Microbiology. The data screening included 
samples taken at inpatient departments and outpa-
tient clinics over a 10-year period (January 2008–
December 2017). In addition, patient data was also 
collected, that were limited to demographic char-
acteristics (age, sex, inpatient/outpatient status) 
and the indication for sample submission. An epi-
sode of candiduria was defined as isolation of Can-
dida spp. from a urine sample of 105 CFU/ml or 
higher on at least one occasion [13]. Isolates were 
considered separate if they occurred more than 
30 days apart or different Candida species were 
isolated.
Identification of isolates
A total of 10 μL of each un-centrifuged and ho-
mogenized urine sample was cultured on UriSe-
lect agar plates (Bio-Rad, Berkeley, CA, USA) with 
a calibrated loop, according to the manufacturer's 
instructions and incubated at 35 ±2°C for 24 hours, 
aerobically. If the pathogen presented in a signifi-
cant colony count of 105 or more CFU/ml and Can-
dida spp. was suspected, a colony was inspected 
using microscopy (i.e. wet mount) and the plates 
were passed on for additional processing. Fungal 
isolates were identified based on colony morphol-
ogy on Sabouraud Chloramphenicol Agar (Bio-Rad, 
Berkeley, CA, USA), germ tube production, micro-
morphology on BD Difco Rice Extract Agar (Becton 
Dickinson Gmbh, Heidelberg, Germany) and BBL 
CHROMagar Candida (Becton Dickinson Gmbh, 
Heidelberg, Germany). If identification was un-
successful using phenotypic/biochemical methods, 
matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS) was 
used. Mass spectrometry was performed by the Mi-
croflex MALDI Biotyper (Bruker Daltonics, Ger-
many) in positive linear mode across the m/z range 
of 2 to 20 kDa; for each spectrum, 240 laser shots 
at 60 Hz in groups of 40 shots per sampling area 
were collected. The MALDI Biotyper RTC 3.1 soft-
ware (Bruker Daltonics, Germany) and the MALDI 
Biotyper Library 3.1 were used for spectrum analy-
sis. Antifungal susceptibility testing is not routine-
ly performed from urinary isolates. The following 
control strains were used for quality control pur-
poses: Candida albicans ATCC 14053, Candida gla-
genitourinary system (e.g. vulvovaginal candidiasis) 
[8]. In addition, candiduria may serve as a marker 
of disseminated candidaemia, which is associated 
with a crude mortality of 30–40% [9, 10, 11]. Can-
diduria is defined as 104-105 CFU/ml of yeasts de-
tected from urine, whereas a Candida UTI is mainly 
characterized by 105< CFU/ml detected, which usu-
ally corresponds with the symptoms of the patient 
[1, 2]. Candida species may ascend to the urinary tract 
through a colonization focus, either near or directly 
at the urethra (retrograde infection route), however, 
they can enter the upper region of the urinary tract 
through the bloodstream (antegrade infection route) 
[2]. Risk factors of candiduria and Candida urinary 
tract infections are well established, and include 
the female sex, extremes of age, diabetes mellitus, 
prolonged hospitalization, intensive care unit (ICU) 
admission, recent use of broad-spectrum antibiotics 
or immunosuppressants, dysfunction of the bladder 
and urinary stasis, nephrolithiasis, transplantation, 
congenital or structural abnormalities of the urinary 
tract, catheterization and simultaneous bacteriuria 
or bacterial UTIs [12]. It has been established that 
HIV-positive women have higher rates of vaginal 
colonization with Candida, often non-C. albicans 
species [8]. In addition, several studies described the 
increased colonization levels of Candida species on 
almost all mucosal surfaces in HIV-positive patients, 
which (together with the general state of immuno-
suppression of the patient) will lead to higher lev-
els of manifested Candida infections, including the 
genitourinary tract [8]. Yeasts generally have poor 
adherence to bladder mucosa and have no tropism 
regarding the tissues of the urinary system, there-
fore the importance of the abovementioned under-
lying factors (promoting obstruction in the urinary 
system) in the pathogenesis of candiduria (or fungu-
ria in general) is further highlighted [2]. 
The epidemiology of candiduria and Candida UTIs 
varies greatly by region, therefore the assessment of 
local data is essential to evaluate trends over time 
and to reflect on the national situation compared to 
international data. The aim of this study was to as-
sess and compare the prevalence of candiduria and 
UTIs caused by different species of Candida spp. 
among inpatients and outpatients at the Albert 
Szent-Györgyi Clinical Center (Szeged, Hungary) 
retrospectively, during a 10-year study period.
MATERIALS AND METHODS 
Study design
The Albert Szent-Györgyi Clinical Center is an 
1,820-bed (1,465 active and 355 chronic beds, re-
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brata ATCC 90030, Candida tropicalis ATCC 13803, 
Candida parapsilosis ATCC 22019, Candida krusei 
ATCC 14243, Trichophyton mentagrophytes ATCC 
9533, Microsporum canis ATCC 36299, Cryptococ-
cus neoformans var. neoformans IFM 5844, Crypto-
coccus neoformans var. gattii IFM 5845.
Statistical analysis
Statistical analyses were performed with SPSS soft-
ware version 24 (IBM SPSS Statistics for Windows 
24.0, Armonk, NY, IBM Corp.), using the χ2-test and 
Student's t-test. P values below 0.05 were considered 
statistically significant.
RESULTS
Demographic characteristics, sample types
The median age was 72.01 years (range: 0.30–99.38) 
in the inpatient group with a female-to-male ratio 
of 2.15; while in the outpatient group, the median 
age was 69.74 years (range: 0.03–93.31) with a fe-
male-to-male ratio of 1.79. No statistically signifi-
cant difference was observed between the patient 
characteristics (p >0.05), however, a predominance 
of patients over 50 years of age could be noted 
in both patient groups (75.0% for inpatients and 
84.25% for outpatients, respectively). Most (99.8%) 
of samples from outpatient clinics were voided 
(midstream) urine, while the majority (87.59%) 
from the inpatient departments were catheter-spec-
imen urine, midstream urine (12.06%) and samples 
obtained through suprapubic bladder aspiration 
(0.3%) were less relevant.
Prevalence and distribution of Candida isolates 
from inpatient and outpatient urine samples
In the 10-year study period, the Institute of Clini-
cal Microbiology received, on average, 2115 positive 
urine samples/year from outpatient clinics and 1933 
positive samples/year from inpatient departments, 
where a significant urinary pathogen was isolated. 
Candiduria was detected in 0.11–0.75% of positive 
urine samples from outpatients, while this number 
was significantly higher for inpatients, ranging be-
tween 3.49–0.63% (p <0.001) (Table 1).
In the outpatient group, urinary tract infection was 
the indication for sample submission in 19.56% 
of cases, whereas in the inpatient group, a sus-
pected UTI or a urinary system-related pathology 
was noted in 6.08% and the suspicion of septicemia 
in 6.89% as the reason for sample submission. The 
distribution of species isolated during the study pe-
riod is presented in Figure 1. The prevalence of C. 
albicans has remained relatively constant through-
out the study period; there was no significant change 
in the ratio of isolation throughout the 10-year period 
(p >0.05). Overall, C. albicans was isolated in 65.22% 
(outpatients) and 59.64% (inpatients), respectively. 
It is worth noting that the prevalence of NACS can-
not be neglected (especially C. glabrata and C. tropi-
calis, accounting for ~20% of outpatient and ~30% 
of inpatient isolates), although there were no signifi-
cant changes observed in their frequency of isolation 
(p >0.05). In a small proportion of samples, Candida 
spp. was isolated together with another urinary tract 
pathogen (mainly Escherichia coli and Enterococcus 
faecalis) or two fungal isolates were present simulta-
neously (predominantly C. albicans with C. glabrata) 
Table 1. Prevalence of Candida spp. in positive urine samples 2008-2017
Outpatients Inpatients
Year No. of positive urine samples % of samples with Candida spp. No. of positive urine samples % of samples with Candida spp.
2008 1753 0.11% 1478 5.01%
2009 1798 0.22% 1546 3.49%
2010 1887 0.48% 1629 3.81%
2011 1862 0.25% 1818 4.24%
2012 1803 0.28% 1952 4.20%
2013 2005 0.40% 2013 5.51%
2014 2245 0.62% 2250 7.33%
2015 2596 0.65% 2312 6.36%
2016 2544 0.75% 2229 9.60%
2017 2657 0.49% 2098 10.63%
Overall 21 150 0.43%  ±0.24%* 19 325 6.02% ±2.47%*
*represents the 10-year average and standard deviation
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trast, other azoles (e.g. itraconazole, voriconazole), 
flucytosine and amphotericin B are less favorable 
therapeutic options (both due to pharmacokinet-
ics and adverse events associated with their use) 
and should be considered in refractory infections 
with fluconazole-resistant strains [22, 23]. This 
phenomenon may explain the rise in the isolation 
of fluconazole non-susceptible NACS (especially 
C. glabrata), which has been linked with prior ex-
posure to fluconazole [19, 24]. Clinicians therefore 
need to be aware of the etiological role of NACS spe-
cies (namely C. glabrata, C. tropicalis, C. parapsilo-
sis, C. guilliermondi, C. krusei and C. lusitaniae) as 
there are therapeutic consequences corresponding 
with their isolation [17, 22, 27].
Based on the results of this retrospective survey, the 
most prevalent isolate at our tertiary-care center re-
mains C. albicans, however, a noteworthy difference 
could be observed in the number of different species 
(5 vs. 10 species) detected in the samples from inpa-
tient and outpatient departments. Hospitalization, 
a pronounced female dominance (1.7–2.15-times 
higher) and the advanced age (~70 years) of many 
affected patients is in line with the findings in lit-
erature [3, 5, 6, 7, 12, 18, 27, 29]. The presence 
of C. glabrata as a relevant etiologic agent of urinary 
tract infections is noteworthy, mainly due to its in-
creasing non-susceptibility to commonly used anti-
[14]. The frequency of yeast-yeast or yeast-bacteria 
co-isolation was 4.28% for outpatients and 8.33% for 
inpatients (p <0.033). 
DISCUSSION
Urinary tract infections are a major cause of mor-
bidity and present a considerable economic burden 
worldwide [15, 16]. The treatment of urinary tract 
infections (especially in settings where healthcare-
related and human resources are scarce) may be 
based on epidemiological data and empiric antibi-
otic treatment [17]. This, however, carries the risk 
of not considering yeasts as probable causative 
agents of UTIs, which in turn will distort local 
epidemiological data and more importantly, may 
hinder the patient in receiving appropriate anti-
microbial therapy [18]. Some routine laboratories 
do not perform the identification or even cultiva-
tion of yeasts from urine samples. Many publica-
tions indicate that Candida albicans is the most 
frequently isolated species however, an increase 
in the occurrence of non-albicans Candida spe-
cies (NACS) has been reported [3, 18, 19, 20]. The 
drug of choice for proven Candida UTIs is usually 
fluconazole, because of the advantageous pharma-
cokinetic parameters (the drug is concentrated in 
the urine) of this antifungal agent [21]. In con-
Figure 1. Distribution of Candida isolates form inpatient and outpatient samples 2008–2017.
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is presented regarding the resistance trends in the 
isolated fungal strains [28].
CONCLUSIONS
The aim of the present study was to highlight the in-
cidence of candiduria in a tertiary-care teaching hos-
pital over a long period of surveillance. Candiduria 
is most common in the nosocomial settings, i.e., 
in patients with indwelling urinary catheters, previ-
ous antibiotic use, abnormality of the genitourinary 
system, surgical intervention or immunosuppression 
(even diabetes mellitus); physicians tasked with the 
care of affected patients need to be aware of this phe-
nomenon. In the majority of cases, candiduria is as-
ymptomatic and antifungal therapy is not required. 
However, from the clinician's point of view, an indi-
vidualized approach needs to drive therapeutic deci-
sions. After the validation of candiduria by the mi-
crobiology laboratory, the physicians need to stratify 
by the presence/absence of relevant risk factors (re-
nal functions, involvement of the genitourinary 
system, immune status). The precise (species-level) 
identification of Candida spp. may become necessary 
in complicated cases to aid the decision on antifun-
gal therapy, and in addition to evaluate the response 
of the patient regarding the already administered 
antifungal drug.
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fungal agents (acquired resistance is also more and 
more frequent), most importantly fluconazole [25]. 
However, the frequency of its isolation was constant 
between 2008–2017, with no significant increasing 
tendencies. To the best of our knowledge this is the 
first and longest-spanning study reporting on the 
prevalence of candiduria (and UTIs caused by Can-
dida spp. by proxy) in Hungary. 
Based on our results, a positive urine sample was 
received by the Institute of Clinical Microbiology 
every three to four days, where significant growth 
of Candida spp. was detected. In these cases, the con-
tinuous communication between physicians and the 
diagnostic microbiology laboratory is crucial [12]. 
The role of the laboratory is to supply clinically rel-
evant information in a precise and timely manner, 
which should be reciprocated by the feedback from 
the physicians, beginning from the submission of the 
sample, followed by information regarding the symp-
toms of the patient and the clinical picture. This way, 
the microbiologists can also consider the possibility 
of the isolated yeasts as contaminants or possible 
causative agents [2, 28, 29].
Some limitations of this study must be acknowl-
edged. Firstly, the presence and nature of symptoms 
of the patients are unknown, which would be a criti-
cal parameter in the differentiation of contamina-
tion (although in these cases 105 CFU/ml is rare 
[2]), colonization and true infection. In addition, 
due to the inability to access the medical records 
of the individual patients affected, the correlation 
between the existence of relevant risk underly-
ing illnesses (e.g., Type 2 diabetes, recent courses 
of broad-spectrum antibiotics, iatrogenic or disease-
related immunosuppression) and candiduria could 
not be assessed [28, 30]. Furthermore, antifungal 
susceptibility testing of the isolated Candida spe-
cies was not performed, therefore no information 
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